Inhibition of Filamentation Can Be Used To Treat Disseminated Candidiasis
- 1 October 2006
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (10), 3312-3316
- https://doi.org/10.1128/aac.00628-06
Abstract
Candida albicans remains the leading causative agent of invasive fungal infection. Although the importance of filamentation in C. albicans pathogenesis has been extensively investigated, in vivo studies to date have been unable to dissect the role of this developmental process in the establishment of infection versus the development of active disease as characterized by damage to the host leading to mortality. To address this issue, we genetically engineered a C. albicans tet-NRG1 strain in which filamentation and virulence can be modulated both in vitro and in vivo simply by the presence or absence of doxycycline (DOX): this strain enabled us, in a prior study, to demonstrate that yeast-form cells were able to infect the deep organs but caused no disease unless filamentation (induced by the addition of DOX) was allowed to occur. In the present study, we examined whether inhibiting filamentation (by withdrawing the DOX) at 24 or 48 h postinfection could serve as an effective therapeutic intervention against candidiasis. The results obtained indicate that DOX removal led to an alteration in the morphology of the infecting fungal cells and a dramatic increase in survival, but as with conventional antifungal drug therapy regimens, mortality rates increased markedly the longer this intervention was delayed. These observations reinforce the importance of invasive filamentous growth in causing the damage to the host and the lethality associated with active disease and suggest this process could be fruitfully targeted for the development of new antifungal agents.This publication has 18 references indexed in Scilit:
- Time to Initiation of Fluconazole Therapy Impacts Mortality in Patients with Candidemia: A Multi‐Institutional StudyClinical Infectious Diseases, 2006
- Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital MortalityAntimicrobial Agents and Chemotherapy, 2005
- Small-Molecule Inhibitors of the Budded-to-Hyphal-Form Transition in the Pathogenic Yeast Candida albicansAntimicrobial Agents and Chemotherapy, 2005
- Need for Early Antifungal Treatment Confirmed in Experimental Disseminated Candida albicans InfectionAntimicrobial Agents and Chemotherapy, 2004
- Candidemia at a Tertiary-Care Hospital: Epidemiology, Treatment, Clinical Outcome and Risk Factors for DeathEuropean Journal of Clinical Microbiology & Infectious Diseases, 2002
- The Direct Cost and Incidence of Systemic Fungal InfectionsValue in Health, 2002
- Nonfilamentous C. albicans Mutants Are AvirulentCell, 1997
- Suppression of Hyphal Formation in Candida albicans by Mutation of a STE12 HomologScience, 1994
- Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990The Journal of Infectious Diseases, 1993
- Hospital-acquired candidemia. The attributable mortality and excess length of stayArchives of Internal Medicine, 1988